Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Creo Medical Group Plc LSE:CREO London Ordinary Share GB00BZ1BLL44 ORD GBP0.001
  Price Change % Change Share Price Shares Traded Last Trade
  2.00 2.17% 94.00 17,294 16:35:05
Bid Price Offer Price High Price Low Price Open Price
90.00 94.00 92.00 90.50 92.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 25.16 -30.34 -15.00 170
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:05 O 10 94.00 GBX

Creo Medical (CREO) Latest News

More Creo Medical News
Creo Medical Investors    Creo Medical Takeover Rumours

Creo Medical (CREO) Discussions and Chat

Creo Medical Forums and Chat

Date Time Title Posts
28/6/202209:40Creo Medical Group... 2017438
03/12/201812:41First use of Speedboat in mainland Europe-
09/12/201614:52China Real Estate Opportunities3
27/6/201212:52having a look......1,095

Add a New Thread

Creo Medical (CREO) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Creo Medical trades in real-time

Creo Medical (CREO) Top Chat Posts

DateSubject
01/7/2022
09:20
Creo Medical Daily Update: Creo Medical Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker CREO. The last closing price for Creo Medical was 92p.
Creo Medical Group Plc has a 4 week average price of 90p and a 12 week average price of 90p.
The 1 year high share price is 206p while the 1 year low share price is currently 90p.
There are currently 181,204,996 shares in issue and the average daily traded volume is 112,633 shares. The market capitalisation of Creo Medical Group Plc is £170,332,696.24.
30/5/2022
13:59
edwardt: the question is how much dilution do we have to endure get there? also i suspect intuitive will potentially drop £30m with ease to buy a stake in creo if they see its potential post trials. all conjecture but creo appears to have a product that is better than those of the big boys which i put a lot of value on.
30/5/2022
13:55
edwardt: fair point - mine was a crude comparison. i just think you can look at the size of the potential partnership with intuitive and one can assume given their size a successful partnership could have a huge impact on creo and probably a low impact on intuitive? as such, potentially 5 years out you could easily see £200 /£300m revenue to creo from a tie up with them and not have overly heroic adoption rates. Clearly the market is factoring this in to an extent but i suspect not enough.
24/5/2022
14:37
74tom: Crikey, I'd not done research on Creo prior to today but it appears they've played an absolute blinder with their acquisitions... Quotes like; "maybe but on half the rating of sales to intuitive, i would have thought we should be on a higher ev/sales given the opportunity set given the gearing to this announcement" And then you read yesterday's results and see; "Revenues billed in the period in relation to Speedboat Inject and CROMA totalled £0.3m (2020, £32k). £24.9m was generated through distribution sales of Creo Europe (formally known as Albyn and Boucart). Other operating income of £0.05m in the 12-month period to 31 December 2021 (December 2020: £0.05m) relates to research grants." They paid €5m for Boucart & €27.5m for Albyn, so we can say that they valued them both at ~1x sales and should presumably be worth a total of £28m today. Creo has a market cap of £178m and had £43m cash left at year end, so the market currently values Speedboat at ~£107m or 356x revenues! And yet some PI's think it's hard done by vs intuitive surgical which trades at 12x revenues. Crazy.
23/5/2022
08:36
c3479z: would have thought it would be easier for intuitive just to buy out Creo but may be they haven't done so because Creo would then be a small UK offshoot.
23/5/2022
07:53
buywell3: Yes but all they have committed to is to clinical trials of certain parts of CREO technology ' the Agreement provides a framework to allow joint clinical studies to be undertaken' Clinical trials take years Sorry to pour cold water on any ramps but Intuitive can't afford to take any risk whatsoever regarding CREO technology until it is well proven via the clinical pathway that Intuitive will dictate Clinical trials are also very costly Meantime despite recent acquisition/s CREO losses continue to rise ie from todays Finals: Operating loss of £29.9m for FY 2021 (FY 2020: £23.5m) Plus the cost of additional training is also going to add --- as is the cost of sales staff From the Finals today : · Pipeline of clinicians to be trained under Clinical Education Programme has doubled · 25% increase in the Group's direct sales force since the start of 2021 buywell wonders if the recent Institutional seller will now sell more ? dyor
10/5/2022
22:36
buywell3: What a ridiculously long thread header No wonder not many people can be bothered posting A cash flow statement (CFS) is a financial statement that summarizes the amount of cash and cash equivalents entering and leaving a company. The CFS measures how well a company manages its cash position, meaning how well the company generates cash. The CFS complements the balance sheet and the income statement. advfn data: Creo Medical Cash Flow Statement .....30 Jun 2018 (GBP) .. 31 Dec 2018 (GBP) .. 31 Dec 2019 (GBP).. 31 Dec 2020 (GBP) Operating CF -7.00 ............-14.30.......... -11.85 .............. -16.28 m Pre-Financing CF -7.78........ -15.58 ..........-12.66 ...............-37.25 m Retained CF ...-7.32 ...........30.90 ...........36.46................-35.92 m Operations Cash Flow Operations Cash Flow is the net cash inflow/outflow from operating activities. Pre Financing Cash Flow Pre Financing Cash Flow is the net cash inflow/outflow before financing. Financing includes for example issue of ordinary share capital, debt due within/after one year and capital element of finance lease rental payments. Retained Cash Flow Retained Cash Flow is the net increase/decrease in cash and cash equivalents in the financial period.
04/11/2021
12:23
sinzu: A lot of air to be deflated yet I think. If any IIs' start losing faith here then the share price is going to drop like a stone IMHO.
12/8/2021
22:14
rambutan2: Cash for growth: Proposed Placing to raise a minimum of GBP30 million Launch of Accelerated Book Build Proposed Open Offer to raise up to approximately GBP5 million Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy is pleased to announce a proposed Placing by way of an accelerated bookbuild to raise a minimum of GBP30 million (before expenses) via a conditional placing of new Ordinary Shares at the issue price of 182.5p per share to new and existing institutional investors, to support further growth of the Group and development of its business. The accelerated book build process is expected to close on 13 August 2021, following which the final quantum of the Placing proceeds will be announced. Furthermore, the Company is proposing to raise up to approximately GBP5 million by way of an Open Offer which will be available to all Qualifying Shareholders on the Record Date. https://uk.advfn.com/stock-market/london/creo-medical-CREO/share-news/Creo-Medical-Group-PLC-Proposed-Placing-Open-Off/85821525
04/6/2021
14:04
rambutan2: Final results for the 12 months ended 31 December 2020 A Transformational Year: Significant growth and continued regulatory progress Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces its audited final results for the 12 months ended 31 December 2020 . The Board is pleased to be able to report that, despite the COVID-19 pandemic, the year ended 31 December 2020 was a strong period for Creo marked by significant internal development and expansion, along with the continued development of the Company's suite of devices to complement the Company's CROMA Advanced Energy Platform ("CROMA") and Speedboat device for use in Gastrointestinal ("GI") therapeutic endoscopy. hTtps://creomedical.com/wp-content/uploads/2021/06/Creo-Medical-Group-plc-2020-Annual-Reports-and-Accounts.pdf
04/1/2017
09:56
pecuniarum copia: NOTE: This is a ridiculously long thread header - so you may want to press "Skip Header" Creo Medical Group is focused on the development and commercialisation of minimally invasive surgical devices, initially in the area of gastrointestinal (GI) surgery and lung cancer. Creo Medical Group has conditionally raised £20 million through a placing with institutional and other investors at a placing price of 76 pence per ordinary share. Market capitalisation approximately £61.3 million. PROPOSED PLACING OF 26,315,800 NEW ORDINARY SHARES AT 76 PENCE PER SHARE AND ADMISSION TO TRADING ON AIM Creo Medical Group PLC (CREO), admission to the AIM Market, 9 December 2016. 80,711,745 Issued and fully paid Ordinary Shares of £0.001 each httPs://find-and-update.company-information.service.gov.uk/company/10371794 x x x AIM rule 26 httPs://investors.creomedical.com/investors/rule-26 RNS: 11 November 2021 Appointment of Joint Broker CREO… announces the appointment of Numis as the Company's Joint Broker with immediate effect. Cenkos Securities plc remains Nominated Adviser and Joint Broker to the Company. RNS: 23 December 2021 Exercise of Options CREO… confirms that it has issued, conditional on admission, 90,000 new ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the exercise of share options. It is expected that admission of the Ordinary Shares will occur at 8:00 a.m. on 31 December 2021. Following admission, the Company will have 181,099,186 Ordinary Shares in issue... x x x https://twitter.com/creomedical?lang=en https://twitter.com/CreoMedical/status/1275002010971123713 [22 June 2020] And we're live! We're so excited to share our new website! Join us on our journey to improve patient outcomes with #AdvancedEnergy. Explore: httP://creomedical.com CREO Admission Document, Dec.2016, PDF httPs://investors.creomedical.com/~/media/Files/C/Creo-Medical/investor-docs/results-and-presentations/creo-admission-document-final.pdf 2019 AIM Awards ~ Best AIM companies > Technology = Creo Medical httPs://www.ii.co.uk/analysis-commentary/best-aim-companies-2019-confirmed-ii509438 2020 Video Abstracts ~ Use of Speedboat-RS2... RNS: 11 February 2020 - Video abstracts featuring Speedboat procedures in India httPs://www.videogie.org/article/S2468-4481(19)30344-3/fulltext and also [...] RNS: 3 August 2020 ~ Video abstract published endorsing Speedboat procedure The video abstract, published via an open access content publisher, Thieme Group titled: 'Feasibility of Speedboat RS2 with bipolar radiofrequency energy for peroral endoscopic myotomy in patients with achalasia (with video)' can be viewed online here: [...] x x x RESULTS Info... Documents are available on the Company's website: httPs://investors.creomedical.com/investors/reports-and-presentations Chepstow, Wales - 20 April 2018 - Creo Medical Group plc (AIM: CREO) ("Creo" or the "Company"), a medical device company focused on the emerging field of surgical endoscopy, announces that it has changed its accounting reference date from 30 June to 31 December with immediate effect. Interim and annual reports will be published each year for the 6 months to 30 June and 12 months to 31 December respectively, in accordance with the AIM Rules for Companies. Unaudited interims for the 6 month period ending 30 June 2018 to be published by 30 September 2018, and Audited results for the 18 month period to 31 December 2018 to be published by 30 April 2019. Note: 5 April 2019, CREO published Full results for the 18 months ended 31 December 2018. x x x Follow Link for Latest Shareholding Info... AIM rule 26 httPs://investors.creomedical.com/investors/rule-26 Latest Shareholding RNS... 13 July 2018: Conditional Placing of new Ordinary Shares [@ 125.pence] 23 December 2019: Result of Open Offer [@ 180.pence] 24 December 2019: Director / PDMR Shareholding 27 December 2019: Legal & General Assurance Soc. (LGAS) Below 3% from 3.26% 30 December 2019: TR-1 M&G Plc 5.54% from n/a 07 February 2020: Exercise of Options 19 February 2020: Issue of Equity and Long Term Incentive Plan ("LTIP") 04 March 2020: Exercise of Options 24 July 2020: Director / PDMR Shareholding 11 August 2020: Exercise of Options 24 November 2020: Exercise of Options 19 April 2021: Exercise of Options 30 April 2021: Total Voting Rights (157,940,390) 01 July 2021: Issue of Equity 20 July 2021: Award of Shares - Share Incentive Plan, Dir. Dealings & Issue of Equity 30 July 2021: Total Voting Rights (161,002,002) 12 August 2021: Proposed Placing to raise a minimum of GBP30 million 12 August 2021: Proposed Open Offer to raise up to approx. GBP5 million [@ 182.5pence] 6 September 2021: TR-1 The Capital Group Companies 7.16% total 7 September 2021: Share Capital will consist of 180,901,186 Ordinary Shares 30 September 2021: Total Voting Rights (180,901,186) 24 November 2021: Exercise of Options 30 November 2021: Total Voting Rights (181,009,186) 23 December 2021: Exercise of Options 31 December 2021: Total Voting Rights (181,099,186) 4 February 2022: Total Voting Rights (181,204,996) x x x RNS UPDATE... RNS: 13 September 2018 First placement and use of Speedboat in South Africa. Seven upper GI tract patients successfully treated. Creo… today announces the successful first use of its Speedboat endoscopic advanced energy device in the upper gastrointestinal tract (GI) in seven patients in South Africa. This follows the appointment of the Company's South African sales and distribution partner, First Medical Company, in July 2018... RNS: 17 September 2018 Extension of Distribution Agreement with Hoya Pentax Medical for the Asia-Pacific (APAC) region. Creo Medical Education Programme to be initiated in APAC alongside Market Seeding beginning in Australia. ...Australia will be the first Asia Pacific territory in which Pentax will establish Creo's Clinical Education Program and subsequently seed the market. Pentax will purchase a minimum quantity of CROMA advance energy platforms and Speedboat instruments with the first products expected to be shipped within 3 months. Furthermore, Creo has agreed to extend the term of Pentax's distribution rights in each territory in which Pentax establishes Creo's Clinical Education Programme for a period of 5 years from the date on which Creo's products are registered in such territory... RNS: 17 October 2018 Spain & Benelux Framework Distribution Agreements Agreements covering Spain, the Netherlands, Belgium and Luxembourg First shipment of products to mainland Europe Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has entered into two further framework distribution agreements to provide clinical training and market seeding across the Spanish, Belgian, Dutch and Luxembourg markets for Creo's CROMA advance energy platform and Speedboat products, ahead of their full commercial launch in 2019. RNS: 3 December 2018 First placement and use of Speedboat in Europe Creo… announces the successful first treatment of a patient in mainland Europe using its Speedboat device powered by the Company's CROMA electrosurgery advanced energy platform, in Seville, Spain. Craig Gulliford, Creo's Chief Executive Officer, commented: "Mainland Europe and the US are key markets for the Company and the successful completion of the first procedure in Spain is an important milestone as we roll-out our Clinical Education Programme across Europe initially through our distribution partners covering Spain, the Netherlands, Belgium and Luxembourg. The additional funds raised over the summer have allowed us to expand our training programme to target a wider international group of clinicians and we remain on track with our US commercialisation programme and look forward to updating shareholders on positive progress." RNS: 16 January 2019 First use of Speedboat in the US Creo... announces the successful first treatment of patients in the US using its Speedboat device powered by the Company's CROMA electrosurgery advanced energy platform. Craig Gulliford, Creo's Chief Executive Officer, commented: "The US is clearly a key market for the Company and the successful completion of the first procedures in the United States is another important milestone for us. Over the next few weeks and months we expect to see our Clinical Education Programme expand in the US and we will continue to update shareholders as our training-led commercialisation strategy advances." RNS: 11 February 2019 Additional European Framework Distribution Agreement with PENTAX Medical Agreement covering France, Germany and Italy ...Continuing Creo's education led commercial strategy, Pentax Europe will collaborate with Creo over an 18-month period to advance the roll out of Creo's Clinical Education Programme across these key markets in Europe, educating leading clinicians in the use of Speedboat and the CROMA platform with the aim of ensuring quality control and best patient outcomes... ...PENTAX Europe will commence seeding these markets with Creo's products, with the ultimate objective of entering into a formal long-term distribution agreement once the seeding phase has completed. This agreement follows on from the PENTAX Medical (a division of HOYA Group) distribution agreement covering Asia-Pacific (APAC) which was extended in September last year, as well as the recently announced agreements covering Spain, the Netherlands, Belgium and Luxembourg. In addition, distribution agreements have already been signed covering the UK and South Africa... RNS: 28 March 2019 Update on US Clinical Education Programme Following the first successful treatment of patients in the US with Speedboat, announced in January 2019, Speedboat has now been used successfully by a further four GI surgeons. Furthermore, at a recent scientific conference, Speedboat was demonstrated during a live case to an audience of leading therapeutic GI endoscopists. During the same conference, many of these leading therapeutic endoscopists were able to get a hands-on introductory experience with Speedboat in a training environment with excellent feedback, in particular with regards to the safety profile Speedboat provides the endoscopist. This brings the total number of doctors now trained in the US to six at five hospitals across the East and West coasts. Creo will be working very closely with these centres as further cases are carried out, along with providing a continuing Clinical Education programme. RNS: 25 June 2019 First commercial orders for Speedboat Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has received its first commercial orders for its Speedboat device, the first in a range of gastrointestinal ('GI') devices to be cleared for use with the CROMA Advanced Energy platform which uniquely combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation. The first purchase orders come from two US hospitals and follow on from the successful roll out of the Company's Clinical Education Programme in the US which has now trained seven leading GI Endoscopists across six hospitals. The purchase orders are a follow-on order of the disposable Speedboat devices following the initial sales of products for training purposes... RNS: 10 September 2019 US Clinical Education Programme enters Phase II First training course delivered by key US adopter trained by Creo ...As part of this new phase, three additional US clinicians have been trained by a US GI Endoscopists who performed his first clinical case earlier this year (RNS 1927N, 16 January 2019) and practices at a major US hospital, which was one of the first to place commercial orders for the Company's Speedboat device. RNS: 26 September 2019 Framework Distribution Agreement for India Indian doctors and nurses trained on Speedboat following signing CREO... has entered into a Distribution Partner Framework Agreement (the "Agreement") with MEDITEK SYSTEMS ("Meditek"), to provide clinical training and market seeding across the Indian market for Creo's CROMA Advance Energy platform and suite of products, including the Speedboat device, ahead of their official launch. RNS: 22 October 2019 Commercial Launch of Speedboat at UEG Week in Barcelona [21/23 Oct.19] Demonstration of wider suite of gastro-intestinal products awaiting regulatory clearance ...Creo will be exhibiting at the United European Gastroenterology ('UEG') Week Congress in Barcelona from 21-23, October 2019 show-casing the CROMA Platform... Craig Gulliford, Chief Executive Officer, commented: "The full commercial launch of the Speedboat device, coupled with the opportunity to show-case the wider suite of products at this key event, is another important step for the Company. In addition to the profiling of our technology in the exhibition area, we will also be using the time together with our distribution partners throughout Europe to outline the initial roll out plans for the wider portfolio and use this fantastic opportunity to build further excitement and momentum as we head into 2020." RNS: 20 November 2019 First in-human cases in India Asia's First POEM procedure undertaken using Speedboat Creo… announces that the first mentored, in-human use of its Speedboat device has taken place in India. This announcement follows on from the framework distribution agreement the Company signed with Meditek Systems in September 2019 to provide clinical in-country training, mentoring and market seeding in India for Creo's CROMA Advanced Energy Platform and suite of products. To date, Medical staff from six key healthcare institutions across India have completed training as part of Creo's Clinical Education Programme and the start of in-country mentoring was marked with the first 2 upper GI POEM (Peroral Endoscopic Myotomy) procedures being performed using Speedboat. These are the first POEM procedures in India carried out using the Speedboat device and show the significant advances made towards the future of endoscopic surgery. The procedures were performed by Dr Amit Maydeo and Dr Gaurav Patil at the BIDS (Baldota Institute of Digestive Sciences) hospital in Mumbai... With further mentored clinical cases planned in the coming days in Delhi, Pune and Hyderabad, the expansion of Speedboat and the CROMA Advanced Energy Platform continues to gather pace. As well as India and the US, patients have now been successfully treated using the Speedboat device powered by Creo's CROMA Advanced Energy platform in the UK, South Africa and Mainland Europe. RNS: 2 December 2019 Fundraising, including Firm Placing, to raise a minimum of GBP43.0 million Launch of Accelerated Book Build and Open Offer to raise up to GBP6.6 million [issue price 180 pence] Craig Gulliford, Creo's Chief Executive Officer, commented: "The injection of additional funds ensures that we can fully capitalise on the growing opportunity that endoscopic surgery offers and will help to accelerate the commercial roll-out of our wider suite of patented electrosurgical devices powered by the CROMA Advanced Energy Platform. This also provides us with a platform to explore potential strategic acquisition opportunities in areas where we can identify adjacent technologies or infrastructure that will support our ambitious growth plans." RNS: 23 December 2019 Result of Open Offer CREO... raised total gross proceeds of GBP1.9 million via the Open Offer. Accordingly, the Company has conditionally raised total gross proceeds of GBP51.9 million via the Fundraising. RNS: 30 January 2020 Trading Update ...trading for the year ended 31 December 2019 has been in-line with expectations and the Company continues to make progress in the commercialisation of the CROMA Advanced Energy Platform ("CROMA") and a suite of patented electrosurgical devices. ...The Company expects to see significant growth during 2020 in commercial orders for its Speedboat device. It is in the final stages of agreeing a third-party manufacturing contract to facilitate larger scale production. The Company has already validated the first batches of products from the third-party manufacturer and is confident of the high quality and consistency of production. Craig Gulliford, Chief Executive Officer of Creo, commented: "Following the completion of our suite of products and the development of our distribution network over the last 12 months, the whole team is gearing up for clinical activity with multiple devices. This is based around both existing and new customers and users. The new devices include, what we believe to be, the only triple mode bipolar surgical scissors, the smallest microwave ablation device, and the only non-stick haemostasis device. "Having delivered initial revenues last year, the next few months mark a significant step up for the business. With much appreciated shareholder support, we now have a unique opportunity with game changing devices to develop the business. We are excited to be bringing these capabilities to both endoscopists and surgical users in many disciplines over the next few years. These achievements are testament to the hard work, passion and dedication of the extended Creo team." RNS: 23 March 2020 US FDA Clearance for HS1 Haemostasis Device CREO… the medical device company focused on the emerging field of surgical endoscopy, announces that it has received 510(k) clearance from the US Food & Drug Administration ('FDA') for its HS1 Haemostasis device ('HS1'). The HS1 will be used with Creo's CROMA Advanced Energy Platform ('CROMA') and alongside the already FDA-cleared Speedboat device. This news represents a significant milestone for the Company, being the first of a number of expected regulatory clearances which will bring a suite of devices to the flexible endoscopy markets in the EU and USA... RNS: 20 May 2020 Commercialisation Agreement CREO… announces that it has signed a commercialisation agreement with the Department of Health and Social Care to provide NHS Hospitals with access to the Company's CROMA Advanced Energy Platform ("CROMA") and associated devices for use in Gastrointestinal ("GI") therapeutic endoscopy at preferential rates for a limited period. The National Institute for Health Research ("NIHR") Invention for Innovation ("i4i") Programme supported certain development projects that Creo undertook via a series of funding awards between 2010 and 2015, totalling close to GBP2 million. In accordance with the terms of such funding, Creo has entered into this commercialisation agreement, which is designed to aid the roll-out of CROMA and accompanying consumable GI devices in the UK. The agreement also provides for training for clinicians and nurses on the use of Creo's suite of advanced energy surgery products... RNS: 3 June 2020 Positive NHS health economics data Savings of nearly GBP5,000 per procedure using Speedboat instead of traditional surgery CREO... announces that initial data from the UK's leading user of the Company's Speedboat device demonstrates that the use of Speedboat can save NHS hospitals nearly GBP5,000 per procedure versus a traditional surgical outcome for patients. Health economic data analysed from a cohort of UK patient cases is estimated to have saved in excess of GBP400,000 of NHS funding in just one hospital... ...The full data is expected to be published in October 2020 and the overall costs savings could be higher when the additional follow up costs associated with surgery is factored in. A further announcement will be made once the data is published in full. RNS: 15 June 2020 CE mark for five new devices Key commercial milestone with launch of full suite of GI products CREO… announces a key commercial milestone, with the simultaneous CE marking of five new devices which form the Creo GI (gastro-intestinal) suite of advanced energy devices across four technology platforms. The CE marking of the full range of products provides EU and UK clearance ahead of their commercial launch. Creo expects to introduce the devices into clinical practice and prepare for commercialisation in the second half of the year. The range is designed to be used with the CROMA(TM) Advanced Energy Platform (CROMA), powered by Kamaptive(TM) full-spectrum adaptive technology, a seamless, intuitive integration of multi-modal energy sources, optimised to adapt to the tissue effect required for different procedures. The heavily patented devices are individually optimised to utilise Bipolar radiofrequency (RF) and High frequency microwave (MW) energy for the core tissue effects of dissection, resection, haemostasis and ablation, and form the basis of four individual device platforms... ...The newly CE marked products are: Speedboat(TM) Slim SpydrBlade(TM) Flex MicroBlate(TM) Fine MicroBlate(TM) Flex SlypSeal(TM) Flex RNS: 2 July 2020 Development loan for plasma sterilising product CREO advanced energy platform to combat COVID-19 Cardiff Capital Region City Deal funding to supports CREO Plasma Division CREO... announces that the Group has secured a GBP2m loan from the Cardiff Capital Region ("CCR") to develop Creo's Cool Plasma technology as a method to kill bacteria and viruses and for sterilisation purposes. Creo's technology has both medical and non-medical applications and initial testing has demonstrated that it can be effective for COVID-19 inactivation and decontamination. The Company believes that the technology has the potential for use in wound care, medical device sterilisation, PPE sterilisation, endoscope sterilisation to kill the bacteria associated with urinary tract infections, as well as general sterilisation and cleaning of enclosed environments within the service and transport sectors... RNS: 6 July 2020 Directorate Change, Appointment of Chief Commercial Officer to the Board & Further strengthening of Senior Management team CREO... announces the following change to the Board and strengthening of the Senior Management team. Appointment of David Woods as Executive Director (previously Non-Exec) David Woods, Non-Executive Director, has been appointed as Chief Commercial Officer ('CCO'), with effect from 1 August 2020. David has extensive experience in the med-tech sector and joins the Company in his new full-time executive role based in the USA, having previously been the President and CEO of PENTAX Americas and M&A Director of HOYA Group PENTAX Medical... RNS: 24 July 2020 Acquisition of Albyn Medical S.L. Supplier of specialist healthcare products adds European commercial platform to Creo CREO... announces the acquisition of Albyn Medical S.L. ("Albyn Medical"), a European specialist in the supply and manufacture of Gastroenterology, Urology and Endoscopy products to healthcare providers, for an equity value of EUR24.8m plus up to EUR2.7m of performance related consideration payable over the next two years. Synergistic acquisition that provides immediate market access With a sales and marketing team of nearly 40 people and a direct presence in Spain, France, Germany and the UK, the acquisition of Albyn Medical fits with the strategy set out by Creo at the time of its fundraising last year and provides it with a commercial and distribution platform to accelerate the development of its business in Europe. Albyn Medical focuses on gastrointestinal ( " GI") products and the acquisition provides a direct route-to-market for Creo's full suite of CE marked GI advanced energy devices... RNS: 23 September 2020 Half-year Report Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces its unaudited results for the six-month period ended 30 June 2020, in line with management expectations... RNS: 2 November 2020 US FDA clearance for MicroBlate (TM) Fine device CREO... announces that it has received 510(k) clearance from the US Food & Drug Administration ('FDA') for its tissue ablation device MicroBlate (TM) Fine. This is the third device to gain FDA regulatory clearance within Creo's portfolio of flexible endoscopy devices for the gastrointestinal ('GI') market alongside SlypSeal(TM) Flex and Speedboat(TM) Inject. The range is designed to be used with the CROMA Advanced Energy Platform, powered by Kamaptive(TM) full-spectrum adaptive technology, a seamless, intuitive integration of multi-modal energy sources, optimised to adapt to the tissue effect required for different procedures such as resection, dissection, coagulation and ablation of tissue... RNS: 3 November 2020 Acquisition of Boucart Medical SRL Belgium based supplier of GI Endoscopy products, complementing Albyn Medical's product range CREO... is pleased to announce the acquisition of Boucart Medical SRL ("Boucart Medical"), the largest independent supplier of gastrointestinal ("GI") endoscopy consumables in Belgium and Luxembourg, for an initial consideration of EUR4.5 million in cash (subject to closing adjustments for cash, debt and working capital) plus up to EUR0.5 million of performance related consideration payable in cash over the next two years... RNS: 9 December 2020 First clinical use of new Creo GI product CREO... announces the first in-man clinical use of its MicroBlate(TM) Fine device, believed to be the world's smallest fine needle microwave ablation device available for clinical practice. The device was used to successfully ablate pancreatic tumour tissue under Endoscopic Ultrasound guidance, without any procedural complications... RNS: 7 January 2021 US FDA clearance for MicroBlate (TM) Flex device CREO... announces that it has received 510(k) clearance from the US Food & Drug Administration ('FDA') for its tissue ablation device MicroBlate(TM) Flex. MicroBlate(TM) Flex is the fourth device within Creo's portfolio of flexible endoscopy devices for the gastrointestinal ('GI') market to receive FDA regulatory clearance, alongside CE marking already received across the range in 2020. The first Creo product to receive FDA clearance, Speedboat(TM) Inject, is being used by clinicians in the UK, EU, US, South Africa and APAC... RNS: 17 February 2021 Trading update Strong regulatory and commercial progress achieved despite worldwide COVID-19 restrictions CREO… announces that trading for the year ended 31 December 2020 was marginally ahead of management expectations, with revenue for the year ended 31 December 2020 increasing to over GBP9m (2019: GBP0.01m). The Company had a net cash position at 31 December 2020 in excess of GBP45m... Craig Gulliford, Chief Executive Officer of Creo, commented: "Despite COVID-19 having a short-term impact on the business, the last 12 months has been a period of transformational change for the Company. At the start of the pandemic, we asked the Creo team to focus on what they can achieve not what they can't achieve; I believe that they have done just that. "In addition to stepping up to provide our own COVID response in local communities, we have gained further CE marks and FDA regulatory approvals for our devices, organically grown talent and completed the acquisitions of Albyn Medical S.L. and Boucart Medical SRL . The regionalised nature of the Group's business hedges against pandemic related travel restrictions. With the roll out of COVID-19 vaccines underway, we look forward to realising our goals this year and beyond." RNS: 19 May 2021 Trading update Q1 trading ahead of management's expectations Increase in elective surgeries driven by need to reduce case backlogs CREO… provides an update on progress and Q1 2021 trading, which is ahead of management's expectations. As a result, the directors have upgraded guidance for year-end revenue performance by at least 10%. As previously stated, trading for the year ended 31 December 2020 was ahead of management's expectations, and the Company expects to report revenues of over GBP9m (2019: GBP0.01m) when it publishes its Audited Report and Accounts in early June... Craig Gulliford, Chief Executive Officer of Creo, commented: " The worldwide uncertainty created by COVID-19 continues; however, the team at Creo has delivered exceptional results across many fronts including, making significant clinical and technical advances, building a global commercial team, finding innovative ways to train clinicians and continuing to deliver revenue ahead of management's expectation into the new financial year. We are delighted with the progress that has been made and believe our products will have a big part to play in reducing costs associated with traditional open surgery, reducing the huge backlogs for elective surgery that have built up during the pandemic, and most importantly providing better outcomes for patients globally." RNS: 26 May 2021 Further health economics data validates technology CREO… announces that data from the paper titled: 'Cost-effectiveness analysis of Speedboat submucosal dissection in the management of large non-pedunculated colorectal polyps' demonstrates that the use of Speedboat Inject is highly likely to be a cost-effective strategy for treating both benign and malignant large non-pedunculated colorectal polyps(1) ("LNPCP") and can lead to cost savings in NHS Hospitals of over GBP10,000 per procedure versus a traditional surgical outcome for patients, a saving of approximately 50 per cent. This is double the saving of that which was first suggested and announced by Creo in June 2020... Craig Gulliford, Chief Executive Officer of Creo, commented: "We are extremely pleased to see this health economics data providing evidence that our Speedboat procedure could save the NHS over GBP10,000 per procedure. Our passion has always been to improve patient outcomes, not only through developing innovate medical devices to bring advanced energy to endoscopy, but to also offer economic benefits to healthcare providers, in turn allowing their limited resources to be applied elsewhere; this data demonstrates that. Following the commercial agreement we signed with the Department of Health and Social Care in 2020, offering health service bodies access to our devices at preferential rates, we continue our efforts to train more surgeons to use our technology, allowing the patients and NHS to benefit." RNS: 4 June 2021 Final results for the 12 months ended 31 December 2020 A Transformational Year: Significant growth and continued regulatory progress CREO… announces its audited final results for the 12 months ended 31 December 2020. The Board is pleased to be able to report that, despite the COVID-19 pandemic, the year ended 31 December 2020 was a strong period for Creo marked by significant internal development and expansion, along with the continued development of the Company's suite of devices to complement the Company's CROMA Advanced Energy Platform ("CROMA") and Speedboat device for use in Gastrointestinal ("GI") therapeutic endoscopy... Financial Highlights : Total sales in the period were GBP9.4m (2019: GBP0.01m) Cash and cash equivalents of GBP45.1m at 31 December 2020 (31 December 2019: GBP81.0m) Operating loss of GBP23.5m (2019: GBP18.9m) including GBP0.7m share based payments, in line with management expectations and reflects increased R&D and commercial activities. Net cash outflow from operating activities of GBP16.3m (2019: GBP11.9m) RNS: 14 June 2021 Acquisition of freehold site for GBP4.25m Expansion of Chepstow footprint to support commercial roll-out CREO… announces that it has exchanged contracts to acquire the freehold interest in the current site of Creo House, the Company's main headquarters in Chepstow ('Unit 2'), as well as the adjacent site ('Units 6-9') for a total consideration of GBP4.25 million in cash. Creo expects to complete the acquisition in early July... Craig Gulliford, Chief Executive Officer of Creo, commented: " We are delighted to have secured the freehold of Creo House as well as the adjacent site which, subject to planning permission, will provide increased capacity to support our commercial, operational and logistic footprint across Europe; as well as providing additional manufacturing capacity for the commercial roll-out of the full suite of advanced energy devices. By acquiring these sites, we are not only showing a firm commitment to Wales, but we are also giving our workforce even greater stability. The expansion is reflective of the rapid growth within Creo." RNS: 16 June 2021 MicroBlate Fine's first in-human use update Life-changing FDA cleared Creo device successful in adding months to patient's life expectancy and well-being CREO… provides an update on its 510(k) US Food & Drug Administration ('FDA') cleared tissue ablation device MicroBlate(TM) Fine... Craig Gulliford, Chief Executive Officer of Creo, commented: "We are delighted to report such a positive update on our 510(k) US Food & Drug Administration cleared tissue ablation device MicroBlate(TM) Fine. The device was successfully used for the first in-human minimally invasive EUS guided treatment in a patient with an unresectable pancreatic neuroendocrine tumour in December 2020. The outcome of the procedure was a success, with subsequent follow up scans not only showing no return of the tumour, but also an absence of any obvious scar tissue." RNS: 6 July 2021 Completion of freehold site for GBP4.25m CREO… confirms that further to the announcement of 14 June 2021, that it has completed the freehold purchase of Creo House, the Company's main headquarters in Chepstow, as well as the adjacent site, from Fastnet Property Investments Limited, the original developer of the site. RNS: 16 July 2021 Opening of United States, East Coast Headquarters CREO… announces that it has opened its United States headquarters at the Summit, Danbury, Connecticut, USA... Craig Gulliford, Chief Executive Officer of Creo, said: "We are delighted and proud to have opened our first United States facility, illustrating our commitment to growth and our focus on the key United States Market. These new premises will provide an excellent working environment for our United States team and a platform to attract further talent in this key region of the United States market." David Woods, Chief Commercial Officer of Creo, commented: "Since my appointment in August last year, I have been busy assembling an experienced team to help capitalise on our continued evolution and expansion as a leading medical device Company. The opening of this clinical training and commercial support facility in the United States represents the next phase in our planned and sustained development and further illustrates our growth and focus in the United States region, which gives even greater access to another important market." RNS: 12 August 2021 Proposed Placing to raise a minimum of GBP30 million Launch of Accelerated Book Build Proposed Open Offer to raise up to approximately GBP5 million Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy is pleased to announce a proposed Placing by way of an accelerated bookbuild to raise a minimum of GBP30 million (before expenses) via a conditional placing of new Ordinary Shares at the issue price of 182.5p per share to new and existing institutional investors, to support further growth of the Group and development of its business. The accelerated book build process is expected to close on 13 August 2021, following which the final quantum of the Placing proceeds will be announced. Furthermore, the Company is proposing to raise up to approximately GBP5 million by way of an Open Offer which will be available to all Qualifying Shareholders on the Record Date… ...A circular, containing further details of the Fundraising and notice of the General Meeting to be held at 10.00 a.m. on 6 September 2021 to, inter alia, approve the Resolutions required to implement the Fundraising, is expected to be published and despatched to Shareholders on 16 August 2021 (the "Circular"). Following its publication, the Circular will be available on the Company's website at httPs://www.creomedical.com/investors RNS: 13 August 2021 Result of Placing The Company is pleased to announce that, further to the announcement made on 12 August 2021 (RNS No:5145I) regarding the Fundraising (the "Launch Announcement"), an aggregate of 17,123,288 Placing Shares have been successfully placed by Cenkos Securities plc at an Issue Price of 182.5 pence per share to raise gross proceeds for the Company of approximately GBP31.25 million... ...This announcement should be read in conjunction with the full text of the Circular to be posted to Shareholders on 16 August 2021, copies of which shall be available on the Company's website at www.creomedical.com RNS: 6 September 2021 Results of Placing and Open Offer and Result of General Meeting On 16 August 2021, Creo announced it had raised GBP31.25 million by way of a conditional Placing and subsequently launched an Open Offer to raise up to an additional GBP5.07 million. The Company is pleased to announce that at its General Meeting held today all of the resolutions, as set out in the Circular dated 16 August 2021, were duly passed. The Company is also pleased to announce the results of the Open Offer, which closed for acceptances at 11:00 a.m. on 3 September 2021 and was significantly oversubscribed. Valid acceptances have been received in respect of 6,609,936 Open Offer Shares, representing 238.1 per cent. of the Open Offer Shares available under the Open Offer… ...The Company has therefore raised gross proceeds of approximately GBP5.07 million through the Open Offer. Application has been made for a total of 19,899,184 new Ordinary Shares, to be issued pursuant to the Placing and Open Offer to be admitted to trading on AIM. It is expected that Admission and dealings in the 19,899,184 new Ordinary Shares will commence at 8.00 a.m. on 7 September 2021. Following Admission, the Enlarged Share Capital of the Company will consist of 180,901,186 Ordinary Shares. RNS: 30 September 2021 Half-year Report CREO… announces its unaudited results for the six-month period ended 30 June 2021. Total sales in the period of GBP12.9m (H1 2020: GBP0.0m) Cash and cash equivalents (before post-period equity raise) of GBP30.6m at 30 June 2021 (H1 2020: GBP70.6m) Operating loss of GBP11.4m for H1 2021 (H1 2020: GBP10.6m) including GBP0.6m share based payments (H1 2020: GBP0.5m), in line with management expectations Net assets of GBP52.2m at 30 June 2021 (H1 2020: GBP74.2m) Strengthened IP portfolio, with 326 granted patents and 810 pending applications as at 31 August 2021 RNS: 11 November 2021 Appointment of Joint Broker CREO… announces the appointment of Numis as the Company's Joint Broker with immediate effect. Cenkos Securities plc remains Nominated Adviser and Joint Broker to the Company. RNS: 12 November 2021 Acquisition of Aber Electronics Limited CREO… announces the acquisition of Aber Electronics Limited ("Aber"), a UK based manufacturer and designer of power amplifiers and radio frequency products, for a fixed cash consideration, plus a contingent consideration over three years. Creo is an existing customer of Aber, using its products within the CROMA Advanced Energy Platform. This acquisition will complement Creo's research, design and manufacturing processes, provide additional specialist microwave and radio frequency capability and expertise within the business and enhance a key element of the Group's supply chain. Creo anticipates leveraging the additional resource and expertise that it has acquired to further develop its Kamaptive Technology, the advanced energy which powers the CROMA Platform… RNS: 24 January 2022 Licensing & Partnership update CREO… provides an update on its Kamaptive Technology ("Kamaptive") licensing and partnership programme. The Company has entered into non-binding heads of terms (the "HoTs") with a number of parties which relate to the Company's SpydrBlade, Cool Plasma and MicroBlate technologies. As outlined previously, Creo is developing its business through a three-tiered Build, Buy and Partner strategy. Having already demonstrated execution on the Build and Buy elements, the Partner strategy aims to create shareholder value through granting third-party access to Creo's advanced energy technology in markets adjacent to those where the Company is already operating. This includes fields such as laparoscopic surgery, robotically assisted surgery, and non-thermal plasma sterilisation. The Company considers these HoTs, to be a key milestone in achieving its stated goal of licensing its technology to established, multi-national partners and is in line with the strategy set out at the time of its fundraising last year. Negotiations on final legally binding agreements are underway and Creo is mobilising resources to deliver against its obligations. The Company will update shareholders as appropriate in due course... RNS: 3 February 2022 Trading update Strong progress against 'Build, Buy and Partner' strategy Revenues ahead of expectations CREO… announces a trading update for the year ended 31 December 2021, as the Company continues to deliver on its three-tiered 'Build, Buy, and Partner' strategy... ...Creo trained a significant number of leading clinicians in 2021, who are now product users, and the Company expects this number to rise in 2022. In order to service this increased demand, Creo has increased its direct sales force by 25% since the beginning of 2021... ...As at 31 December 2021 the Company had a net cash position of approximately GBP44 million... ...Craig Gulliford, Chief Executive Officer of Creo, commented: "I am pleased to report on what has been a successful year for Creo, with strong progress against our 'Build, Buy, and Partner' strategy. We have seen significant growth in commercial orders and adoption of Speedboat Inject in the US and Europe, the successful acquisition of Aber Electronics, as well as agreeing HoTs with a number of third parties to provide access to our advanced energy technology. Particularly encouraging has been completing the transition from a distribution model in core markets to an integrated direct sales team, built from the ground up in the US and through successful integration of Albyn Medical into our European business. "We see the COVID-19 outlook improving, with an increased backlog of doctors gearing up to perform procedures as staffing challenges reduce, and restrictions ease across the globe. "2022 has already started positively, with strong performances seen from our core product portfolio. Throughout the rest of the year, we look forward to continuing to execute and expand our three-tiered strategy through the education and training of clinicians, the roll-out of our product portfolio in APAC and further commercial orders and adoption of Speedboat Inject in the US and Europe. With our strong cash position and clear strategy, Creo is well positioned to deliver shareholder value in 2022. We look forward to updating shareholders in more detail in due course." RNS: 4 February 2022 Award of Shares under Share Incentive Plan, Director Dealings, Issue of Equity and TVR ...The Company has been notified that Yorkshire Building Society, the independent trustee of the SIP, acquired, in accordance with the SIP's rules and on behalf of SIP participants, 54,404 ordinary shares in the Company ("Ordinary Shares"), at a price of GBP1.277 per Ordinary Share to meet its obligations under the SIP. Under the terms of the SIP, the Company is required to issue to the SIP, two Ordinary Shares in the Company for each Partnership Share purchased, being 105,810 new Ordinary Shares (having taken into account 2,998 ordinary shares held by the Trust which were previously allocated to employees who ceased employment before the shares had vested). These new Ordinary Shares will be held by Yorkshire Building Society as trustee of the SIP... Total Voting Rights (TVR) The above figure of 181,204,996 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. RNS: 16 March 2022 Albyn Medical earn out update CREO… provides an update on the earn out agreement related to the acquisition of Albyn Medical S.L. ("Albyn"), as announced on 24 July 2020. ...The Company confirms that due to the successful performance of Albyn, the Company has acquired 50% of the remaining 10% of the issued share capital of Albyn for a consideration of EUR1.2m and the first tranche of the Earn Out payment, being EUR1.7m, has been satisfied in cash. The successful acquisition has increased the Group's revenue year-on-year and the integration of Creo's European direct sales teams is now yielding new users of the Group's core technology. Albyn is now operating under the Creo Medical brand with its product range offering a mix of proprietary technology, own-brand labelled and third-party devices providing diagnostic, therapeutic and hygiene / cross-contamination control to a customer base of over 4,600, including hospitals, hospital groups and doctors' offices in both the state and private sectors. ...Craig Gulliford, Chief Executive Officer of Creo, commented: "That the Albyn team have successfully fulfilled the acquisition earn out criteria shows that they are performing well in what has been a challenging period given the pandemic, and they are now a fully integrated part of the Group. We're delighted to see that the 'Buy' element of our 'Build, Buy, Partner' strategy is yielding positive results." RNS: 20 April 2022 Creo opens Singapore regional hub Commercial hub further strengthens Creo's footprint across Asia-Pacific region CREO… announces that it has officially opened its regional hub in Singapore, with the first-class facility providing a multi-functional centre for the commercial roll-out of Creo's products across the Asia-Pacific ("APAC") region. The facility will provide a base for Creo's staff working across the region and includes a training centre, demonstration room, service centre and conference room... Craig Gulliford, Chief Executive Officer of Creo, said: "It's fantastic to see this regional hub officially open - it's a first-rate facility which allows Creo to build on the important groundwork already done as we step up and roll out our products to new and exciting audiences and markets. "The demand is clear from the engagement we've already had, and this commercial hub is a key cog in turning that demand into users and, ultimately, better outcomes for patients across APAC, whilst helping to deliver on our 'Build, Buy and Partner' strategy." RNS: 28 April 2022 Trading update and notice of results Solid start to 2022, with revenues in line with expectations CREO… announces a trading update for the first quarter of 2022 and confirms that it expects to publish its final results for the year ended 31 December 2021 in early May 2022. Creo continued to build momentum during 2021 and, as announced in the Company's 3 February 2022 trading update, overall revenue for the year ended 31 December 2021 is expected to be just over GBP25m - in line with the upgraded market expectations for FY2021. This momentum has continued in 2022 YTD with Creo seeing a solid start to the year. Revenues for Q1 2022 are strong, supported by the commercial groundwork put in place during the COVID-19 pandemic, the reopening of markets post COVID-19 and the resultant backlog of demand for elective procedures, increased training and adoption of Creo's Speedboat Inject device. Commercial activity from Creo's core products continues to grow, with notable contributions from the US, EMEA and Asia-Pacific ("APAC") markets where case volumes have increased quarter-on-quarter... Craig Gulliford, Chief Executive Officer of Creo, commented: "I have been delighted with the start to the year that the Creo team has made, as we build on the momentum that we established in 2021. We have seen increased training and adoption of clinicians using Speedboat Inject, with March 2022 being our record month for US cases performed using the device. "The new 'pioneer' training programme demonstrates our commitment to continually improving our training standards to ensure that clinicians are properly educated on the safe use of our products, and become long-term users of our technology. Although our APAC regional hub has only just recently opened, the local Creo team has already made strong progress in building relationships with distribution partners, and we expect the hub to be a strong driver for our international expansion going forward as restrictions are lifted around the region." RNS: 23 May 2022 Final Results Total sales in the period of GBP25.2m (FY 2020: GBP9.4m) Cash and cash equivalents of GBP43.5m at 31 December 2021 (FY 2020: GBP45.1m), including GBP34.3m net raised through Placing and Open Offer in September 2021 R&D expenditure in the year was GBP12.9m (FY 2020: GBP10.2m) Operating loss of GBP29.9m for FY 2021 (FY 2020: GBP23.5m) including GBP2.6m share based payments (FY 2020: GBP0.7m), in-line with management expectations Net assets of GBP73.3m at 31 December 2021 (FY 2020: GBP62.8m) also Collaboration agreement with Intuitive Creo technology to be adapted for use with robotic-assisted surgical platform CREO… announces that it has signed a long-term, multi-year collaboration agreement (the "Agreement") with Intuitive to optimise certain Creo products to be compatible with Intuitive's robotic technology . Intuitive (Nasdaq: ISRG) is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. Along with the optimisation of Creo's products, the Agreement provides a framework to allow joint clinical studies to be undertaken and includes a number of milestone payments to be made to Creo. Future royalty structures have also been agreed for any products which may be sold in the future… RNS: 27 May 2022 Chief Financial Officer purchases 70,000 shares [@ 96.75pence] Non-Executive Chairman purchases 15,435 shares [@ 97.18pence]
Creo Medical share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
CREO
Creo Medic..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220701 17:05:06